Trading platforms tied to prediction markets are starting 2026 with record activity, even as regulators intensify their focus on the sector. Record daily volumeTrading platforms tied to prediction markets are starting 2026 with record activity, even as regulators intensify their focus on the sector. Record daily volume

Regulatory heat fails to cool prediction markets as daily volume hits $702M record

prediction markets

Trading platforms tied to prediction markets are starting 2026 with record activity, even as regulators intensify their focus on the sector.

Record daily volume of $702M kicks off 2026

Prediction-focused platforms ended 2025 on a sharp uptrend and carried that momentum into 2026. According to Dune Analytics, combined trading activity across major venues recently jumped to about $702M in a single day, marking a new all time high for the niche.

Data shows prediction market volume has been rising quickly since late 2025. Kalshi drove most of the action, handling roughly two thirds of total trades, while Polymarket and Opinion also saw heavy usage during the same period.

On Monday, total trading volume reached a fresh ATH of $700M, underscoring how interest continues to accelerate. Moreover, figures shared by analyst Jonaso on January 15, 2026 highlighted that Kalshi generated $460M that day, securing 66.4% of the market.

Meanwhile, Polymarket, Opinion and @trylimitless each captured close to a 14% share, indicating that liquidity is spreading beyond a single venue. However, the leadership position of Kalshi remains clear based on its reported trading dominance.

How prediction markets are evolving in crypto

These on chain venues allow users to trade contracts tied to the outcome of real world events, including elections, macroeconomic data and sports. Over recent months, they have emerged as one of crypto‘s fastest growing applications, supported by rising on chain volumes and user participation.

Moreover, large crypto companies have started to engage with this trend. Coinbase and Gemini are reportedly exploring integrations that would surface event based markets to their customers, while wallet providers such as MetaMask are adding interfaces that give users direct access.

This expansion has helped push leading firms in the space to multi billion dollar valuations, as capital flows into infrastructure and liquidity. That said, the prediction markets narrative is increasingly colliding with regulatory debates that could shape how these platforms operate in the coming years.

For many users, one of the key attractions of prediction markets is the ability to express views on politics, finance and culture using relatively small stakes. However, that same breadth of topics has drawn closer attention from policymakers worried about gambling, market integrity and potential insider trading.

Regulatory scrutiny intensifies on event based trading

Regulators worldwide are now paying closer attention to prediction markets regulation, even as trading volumes climb. A recent high profile position on Polymarket triggered concerns that the trader might have relied on non public information, prompting fresh calls for oversight.

Lawmakers in several US states are reviewing whether certain contracts tied to politics, sports or financial assets should face restrictions or outright bans. Moreover, some jurisdictions are questioning whether existing gambling or securities rules already cover these types of event based markets.

States such as New York and New Jersey have previously attempted to limit access to specific platforms, arguing that the products look similar to unlicensed wagering. In response, operators have pushed back in court, arguing their contracts provide information markets rather than pure gambling products.

This week, the legal battle produced a notable development. A federal judge in Tennessee paused state level action against Kalshi, giving the company temporary relief as it contests the enforcement effort. However, the underlying questions about classification and jurisdiction remain unresolved.

Global pushback and resilient user demand

Outside the United States, authorities have also started to react. Late last year, Ukraine moved to block local access to Polymarket, explicitly framing these services as a form of gambling that should not be available to residents.

Even with these policy headwinds, trading data indicates that users have not stepped back in a meaningful way. Moreover, the recent $702M record day suggests that appetite for event based speculation and hedging remains robust despite mounting regulatory uncertainty.

For now, platforms are trying to balance growth with compliance while investors track both trading metrics and legal developments. In summary, the sector’s trajectory will likely depend on how courts and regulators ultimately define these markets and whether stricter rules impact liquidity over time.

Market Opportunity
Major Logo
Major Price(MAJOR)
$0.13454
$0.13454$0.13454
+4.15%
USD
Major (MAJOR) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

5 High-Growth Cryptos for 2025: BullZilla Tops the Charts as the Best 100x Crypto Presale

5 High-Growth Cryptos for 2025: BullZilla Tops the Charts as the Best 100x Crypto Presale

BullZilla, World Liberty Financial, MoonBull, La Culex, and Polkadot (DOT) are taking the spotlight among emerging and established crypto projects […] The post 5 High-Growth Cryptos for 2025: BullZilla Tops the Charts as the Best 100x Crypto Presale appeared first on Coindoo.
Share
Coindoo2025/10/18 08:15
Over $145M Evaporates In Brutal Long Squeeze

Over $145M Evaporates In Brutal Long Squeeze

The post Over $145M Evaporates In Brutal Long Squeeze appeared on BitcoinEthereumNews.com. Crypto Futures Liquidations: Over $145M Evaporates In Brutal Long Squeeze
Share
BitcoinEthereumNews2026/01/16 11:35
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26